Talking to patients about biosimilars

Yelena Y. Janjigian, Marco Bissig, Giuseppe Curigliano, Jennifer Coppola, Mark Latymer

Research output: Contribution to journalReview articlepeer-review


Biologic therapies target aberrant pathways in diseases including diabetes, cancer and autoimmune disorders. Despite recent scientific advances, patient access to these agents can be limited. Biosimilars are designed to be highly similar to the originator biologic, targeting the same biological pathways, with comparable efficacy and safety. Biosimilars have the advantage of lower treatment costs, offering the potential for increased clinical use and patient access. Several biosimilars are approved for clinical use in the USA and Europe; however, there is a lack of awareness about biosimilars among healthcare providers and patients. This overview of the scientific basis of biosimilars and current indications aim to enhance discussions with patients and increase understanding of the role of biosimilars in individual treatment plans.

Original languageEnglish
Pages (from-to)2403-2414
Number of pages12
JournalFuture Oncology
Issue number23
Publication statusPublished - Oct 1 2018


  • biosimilar
  • healthcare provider
  • patient access
  • patient communication
  • regulatory pathway
  • totality of evidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Talking to patients about biosimilars'. Together they form a unique fingerprint.

Cite this